FDA Greenlights ZYCUBO: A Game-Changer in Treatment Options
July 9, 2026
FDA Greenlights Liraglutide as a New Treatment Option
The FDA has approved Liraglutide for obesity treatment, potentially revolutionizing care for millions. The drug offers a new avenue for weight loss ma...
July 9, 2026
FDA Greenlights MORPHINE SULFATE for Pain Management
The FDA has approved MORPHINE SULFATE, a new treatment for severe pain, priced at $0.85 per milligram, amid the ongoing opioid crisis.
July 9, 2026
FDA Greenlights IMODIUM MULTI-SYMPTOM RELIEF for Consumers
The FDA has approved IMODIUM MULTI-SYMPTOM RELIEF, offering a new treatment for diarrhea, gas, and bloating, available in stores starting April 2015.
July 8, 2026
FDA Grants Approval for OXAPROZIN as Innovative Treatment
The FDA has approved OXAPROZIN, a new drug for chronic pain from arthritis, set to launch in January 2026 at $150 for a 30-day supply.
July 8, 2026
FDA Greenlights HYDROMORPHONE HYDROCHLORIDE for Pain Relief
The FDA has approved HYDROMORPHONE HYDROCHLORIDE, a new opioid analgesic for severe pain management, addressing the critical need for effective pain r...
July 8, 2026
FDA Greenlights Oxycodone Hydrochloride for Pain Relief
The FDA has approved a new formulation of Oxycodone Hydrochloride, offering a safer pain management option amid ongoing opioid crisis concerns.
July 8, 2026
FDA Set to Review Dapagliflozin by December 2025
The FDA is set to make a crucial decision on dapagliflozin by December 2025, influencing diabetes and heart failure treatments.
July 8, 2026
FDA Greenlights CLARAVIS as a New Acne Treatment Option
The FDA has approved CLARAVIS as a new treatment for severe acne, providing hope for patients who have struggled with persistent acne.
July 8, 2026
FDA Greenlights Acetaminophen and Ibuprofen Combination Therapy
The FDA has approved a new combination therapy of acetaminophen and ibuprofen, offering enhanced pain relief at $19.99 for a 30-day supply.
July 8, 2026